Tag : IMMUNOMODULATOR

NEWS AND PERSPECTIVE

Etrasimod receives FDA approval for moderately to severely active UC following the favorable safety and efficacy results of the ELEVATE UC trials
The ELEVATE trial revealed the achievement of significant and sustained clinical remission in patients with moderately to severely active ulcerative colitis (UC) with the induction and maintenance treatment of etrasimod, a novel oral sphingosine 1-phosphate (S1P) receptor modulator. Based on the positive efficacy and safety results of this study, the United States (US) Food and Drug Administration (FDA) has approved etrasimod for the treatment of moderately to severely active UC.